Paris, 22 September 2026 – Biolevate, the company building knowledge-driven automation for life sciences operations, today announced a €30 million Series A funding round co-led by RAISE France – the investment vehicle of French entrepreneur Aymar Hénin, and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F and existing investor EQT Ventures.
Paris, 22 September 2026 – Biolevate, the company building knowledge-driven automation for life sciences operations, today announced a €30 million Series A funding round co-led by RAISE France – the investment vehicle of French entrepreneur Aymar Hénin, and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F and existing investor EQT Ventures.
The funding accelerates Biolevate’s ambition to become the evidence-grade automation layer for regulated life sciences operations globally, and coincides with its expansion into the United States via a new office in Boston, establishing a presence at the heart of the global pharmaceutical ecosystem.
The funding accelerates Biolevate’s ambition to become the evidence-grade automation layer for regulated life sciences operations globally, and coincides with its expansion into the United States via a new office in Boston, establishing a presence at the heart of the global pharmaceutical ecosystem.
Founded in Paris by a team of ex-Dataiku engineers and AI researchers, Biolevate addresses one of the most significant productivity challenges facing the life sciences industry today. With the global pharmaceutical market expected to exceed USD 1.7 trillion by 2030, companies face growing pressure to bring differentiated therapies to market faster. While frontier AI is accelerating drug discovery and development, it is also intensifying route-to-market bottlenecks that delay patient access and hinder commercial growth.
Founded in Paris by a team of ex-Dataiku engineers and AI researchers, Biolevate addresses one of the most significant productivity challenges facing the life sciences industry today. With the global pharmaceutical market expected to exceed USD 1.7 trillion by 2030, companies face growing pressure to bring differentiated therapies to market faster. While frontier AI is accelerating drug discovery and development, it is also intensifying route-to-market bottlenecks that delay patient access and hinder commercial growth.
To address these bottlenecks, Biolevate has developed a hyperspecialised, enterprise-grade agentic platform powered by frontier AI research that transforms complex scientific and regulatory knowledge into evidence-grade, auditable workflows. Unlike general-purpose AI systems, the platform keeps outputs grounded in source evidence at every stage, enabling life sciences organisations to deploy AI confidently in regulated environments while preserving human oversight.
To address these bottlenecks, Biolevate has developed a hyperspecialised, enterprise-grade agentic platform powered by frontier AI research that transforms complex scientific and regulatory knowledge into evidence-grade, auditable workflows. Unlike general-purpose AI systems, the platform keeps outputs grounded in source evidence at every stage, enabling life sciences organisations to deploy AI confidently in regulated environments while preserving human oversight.
Initially built to accelerate regulatory approval workflows, Biolevate’s platform now spans the full life sciences value chain, including research, clinical trials, health technology assessments, regulatory dossiers, drug discovery and drug development. Capable of running 100,000 agents concurrently, Biolevate delivers tangible impact for customers, accelerating systematic literature reviews and research synthesis by 16x, and delivering an 80% efficiency gain in regulatory intelligence and compliance.
Initially built to accelerate regulatory approval workflows, Biolevate’s platform now spans the full life sciences value chain, including research, clinical trials, health technology assessments, regulatory dossiers, drug discovery and drug development. Capable of running 100,000 agents concurrently, Biolevate delivers tangible impact for customers, accelerating systematic literature reviews and research synthesis by 16x, and delivering an 80% efficiency gain in regulatory intelligence and compliance.
Since its seed round in 2024, Biolevate has established partnerships with major organisations across the life sciences ecosystem, including Sanofi, regulators, and technology leaders such as NVIDIA and Microsoft. The company now has more than a dozen enterprise customers in production and has increased annual recurring revenue (ARR) by 20x over the last twelve months. The business has also doubled headcount over the past 12 months to 50 employees and expects to grow its workforce by a further 100% over the coming year. In parallel, Biolevate has drafted seven patent applications across multiple therapeutic areas, two of which have already been filed in Europe.
Since its seed round in 2024, Biolevate has established partnerships with major organisations across the life sciences ecosystem, including Sanofi, regulators, and technology leaders such as NVIDIA and Microsoft. The company now has more than a dozen enterprise customers in production and has increased annual recurring revenue (ARR) by 20x over the last twelve months. The business has also doubled headcount over the past 12 months to 50 employees and expects to grow its workforce by a further 100% over the coming year. In parallel, Biolevate has drafted seven patent applications across multiple therapeutic areas, two of which have already been filed in Europe.
As part of the Series A investment, French entrepreneur Aymar Hénin has been appointed Chairman of Biolevate’s Board of Directors, while Jérôme Berger, Head of Group Strategy & Venture Capital at Orange, joins the Board. Their experience will support Biolevate as the company enters its next phase of international growth.
As part of the Series A investment, French entrepreneur Aymar Hénin has been appointed Chairman of Biolevate’s Board of Directors, while Jérôme Berger, Head of Group Strategy & Venture Capital at Orange, joins the Board. Their experience will support Biolevate as the company enters its next phase of international growth.
Joël Belafa, Co-Founder and CEO at Biolevate, said:
“We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges. Today, our vision is becoming reality. Customers are increasingly embracing AI automation at scale, grounded in evidence and under rigorous human oversight. This milestone, paired with the extraordinary traction we are experiencing, confirms that we are on track to build a global champion in this emerging category and, more importantly, to deliver on AI’s promise for healthcare.”
“We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges. Today, our vision is becoming reality. Customers are increasingly embracing AI automation at scale, grounded in evidence and under rigorous human oversight. This milestone, paired with the extraordinary traction we are experiencing, confirms that we are on track to build a global champion in this emerging category and, more importantly, to deliver on AI’s promise for healthcare.”
Aymar Hénin, Entrepreneur and newly appointed Chairman of Biolevate, said:
“Biolevate is addressing one of the most important challenges in life sciences: turning the extraordinary potential of AI into trusted, evidence-grade automation that can operate at scale in regulated environments. The company’s rapid commercial progress, deep technological expertise and ambitious team give us strong conviction in its ability to become a global category leader. I am proud to support that journey as an investor and to work closely with Joël and the team as Chairman.”
“Biolevate is addressing one of the most important challenges in life sciences: turning the extraordinary potential of AI into trusted, evidence-grade automation that can operate at scale in regulated environments. The company’s rapid commercial progress, deep technological expertise and ambitious team give us strong conviction in its ability to become a global category leader. I am proud to support that journey as an investor and to work closely with Joël and the team as Chairman.”
Jérôme Berger, Head of Group Strategy & Venture Capital at Orange, added:
“In healthcare, the value of AI depends on the trust people can place in the knowledge it produces. Biolevate’s approach to making complex scientific information accessible, reliable and usable, strongly aligns with our vision of responsible AI, and we are delighted to co-lead this new stage of the company’s growth.”
“In healthcare, the value of AI depends on the trust people can place in the knowledge it produces. Biolevate’s approach to making complex scientific information accessible, reliable and usable, strongly aligns with our vision of responsible AI, and we are delighted to co-lead this new stage of the company’s growth.”
– ENDS –
About Biolevate
About Biolevate
Biolevate builds evidence-grade AI for regulated life sciences operations. The platform combines scientific evidence, regulatory knowledge, company context, governed workflows, and AI agents to help teams automate complex work while preserving traceability, auditability, reproducibility, and human control. Biolevate enables life sciences organisations to move beyond isolated AI tools and build knowledge-driven automations that can safely support regulated work at scale.
Biolevate builds evidence-grade AI for regulated life sciences operations. The platform combines scientific evidence, regulatory knowledge, company context, governed workflows, and AI agents to help teams automate complex work while preserving traceability, auditability, reproducibility, and human control. Biolevate enables life sciences organisations to move beyond isolated AI tools and build knowledge-driven automations that can safely support regulated work at scale.
Media Contact
Media Contact
Kekst CNC
Kekst CNC
Victoria Douglas +44 790 8638 573
Victoria Douglas +44 790 8638 573
Camille Apelbaum +33 (7) 88 40 68 55
Camille Apelbaum +33 (7) 88 40 68 55